Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 4:23 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 7,824 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Acute Disease Clear all
Completed No phase listed Observational

Wellness and Quality of Life Perceptions of People With Traumatic Brain Injury

NCT04794894
View directory record Official record
Conditions
Brain Injuries, Traumatic
Interventions
outpatient rehabilitation
Behavioral
Lead sponsor
Quality Living, Inc.
Other
Eligibility
19 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Nov 3, 2026, 4:23 PM EST
Completed Phase 1Phase 2 Interventional Results available

Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia

NCT00096122
View directory record Official record
Conditions
Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Childhood Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Untreated Adult Acute Myeloid Leukemia
Interventions
cytarabine, idarubicin, tipifarnib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
15 Years to 70 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 26, 2014 · Synced Nov 3, 2026, 4:23 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Echinacea and Acute Respiratory Illness

NCT02003651
View directory record Official record
Conditions
Acute Respiratory Infections
Interventions
Quick Defense, Placebo
Dietary Supplement
Lead sponsor
Appalachian State University
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 13, 2016 · Synced Nov 3, 2026, 4:23 PM EST
Completed Phase 2 Interventional

Aminopterin in Treating Patients With Refractory Leukemia

NCT00003305
View directory record Official record
Conditions
Leukemia
Interventions
aminopterin, leucovorin calcium
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
14
States / cities
Anaheim, California • Laguana Hills, California • Waterbury, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Nov 3, 2026, 4:23 PM EST
Completed Phase 2 Interventional

Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders

NCT00005622
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Multiple Myeloma and Malignant Plasma Cell Neoplasms, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
cyclophosphamide, TBI
Drug · Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
15 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2009
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 25, 2012 · Synced Nov 3, 2026, 4:23 PM EST
Terminated Phase 1 Interventional

Study of GDX012 in Patients With MRD Positive AML

NCT05001451
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
GDX012 Suspension for IV Infusion
Biological
Lead sponsor
GammaDelta Therapeutics Limited
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Nov 3, 2026, 4:23 PM EST
Terminated Phase 1 Interventional

A Phase I Trial of Alloreactive Cell Infusion Following Transplantation of Haplotype Cells in Patients With Myeloid Malignancies

NCT00569179
View directory record Official record
Conditions
Leukemia, Myeloid, Acute, Leukemia, Lymphoid, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic
Interventions
CliniMACS CD34 Reagent System
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 31, 2015 · Synced Nov 3, 2026, 4:23 PM EST
Completed Phase 3 Interventional Results available

A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

NCT06059846
View directory record Official record
Conditions
Urinary Tract Infection, Acute Pyelonephritis
Interventions
TBP-PI-HBr, Imipenem-cilastatin, Dummy Infusion, Dummy Tablets
Drug
Lead sponsor
Spero Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
1,690 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Nov 3, 2026, 4:23 PM EST
Completed Phase 1Phase 2 Interventional

Chemotherapy Followed by Donor White Blood Cells Plus Interleukin-2 in Treating Patients With Acute Myeloid or Lymphocytic Leukemia

NCT00005802
View directory record Official record
Conditions
Leukemia
Interventions
aldesleukin, filgrastim, therapeutic allogeneic lymphocytes, cytarabine, etoposide, fludarabine phosphate, methotrexate, mitoxantrone hydrochloride, therapeutic hydrocortisone, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 2, 2010 · Synced Nov 3, 2026, 4:23 PM EST
Terminated Phase 1 Interventional Accepts healthy volunteers

Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML

NCT02255162
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Acute Myelocytic Leukemia, Acute Myelogenous Leukemia, Acute Granulocytic Leukemia, Acute Non-Lymphocytic Leukemia
Interventions
Lenalidomide, HLA-mismatched stem-cell Microtransplantation, Cytarabine
Drug · Genetic
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 18, 2017 · Synced Nov 3, 2026, 4:23 PM EST
Recruiting Phase 2 Interventional

Personalized NK Cell Therapy in CBT

NCT02727803
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Myeloid Leukemia With Variant MLL Translocations, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Chemotherapy-Related Leukemia, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, ISS Stage II Plasma Cell Myeloma, ISS Stage III Plasma Cell Myeloma, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Myelodysplastic Syndrome With Gene Mutation, Myelodysplastic/Myeloproliferative Neoplasm, Previously Treated Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Adult Acute Lymphoblastic Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome
Interventions
Allogeneic Natural Killer Cell Line NK-92, Anti-Thymocyte Globulin, Busulfan, Clofarabine, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Melphalan, Rituximab, Total-Body Irradiation, Umbilical Cord Blood Transplantation
Biological · Drug · Other + 2 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 3, 2026, 4:23 PM EST
Completed Phase 2 Interventional Results available

Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia

NCT01253070
View directory record Official record
Conditions
Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11, Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1, Acute Promyelocytic Leukemia With PML-RARA, FLT3 Gene Mutation, Therapy-Related Acute Myeloid Leukemia
Interventions
Biopsy, Bone Marrow Aspiration, Cytarabine, Daunorubicin Hydrochloride, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration, Sorafenib Tosylate
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
60 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
43
States / cities
Lewes, Delaware • Newark, Delaware • Orlando, Florida + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Nov 3, 2026, 4:23 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

NIRS Monitoring in the NICU and AKI

NCT07222722
View directory record Official record
Conditions
Acute Kidney Injury (AKI), Postnatal AKI
Interventions
NIRS Monitoring
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
24 Weeks to 30 Weeks
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Nov 3, 2026, 4:23 PM EST
Terminated Phase 1Phase 2 Interventional Results available

Topical Irrigation Therapy for CRS

NCT02630472
View directory record Official record
Conditions
Rhinitis, Sinusitis
Interventions
Quinine Sulfate, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Nov 3, 2026, 4:23 PM EST
Terminated Phase 1 Interventional

Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)

NCT02203773
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Myelogenous Leukemia, Treatment Naive AML
Interventions
Posaconazole, ABT-199, Decitabine, Azacitidine
Drug
Lead sponsor
AbbVie
Industry
Eligibility
60 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
13
States / cities
Duarte, California • Sacramento, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Nov 3, 2026, 4:23 PM EST
Completed Phase 1 Interventional

Imatinib Mesylate, Daunorubicin, and Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia

NCT00268229
View directory record Official record
Conditions
Leukemia
Interventions
cytarabine, daunorubicin hydrochloride, imatinib mesylate
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 15, 2013 · Synced Nov 3, 2026, 4:23 PM EST
Completed Phase 2 Interventional

Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare

NCT07145229
View directory record Official record
Conditions
Acute Gouty Arthritis, Gout Flare, Gout Flares, Acute Gout Flare
Interventions
ABP-745 Dose A, ABP-745 Dose B, Colchicine, Placebo
Drug
Lead sponsor
Atom Therapeutics Co., Ltd
Industry
Eligibility
18 Years to 70 Years
Enrollment
479 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
14
States / cities
Peoria, Arizona • La Mesa, California • Norcross, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 3, 2026, 4:23 PM EST
Completed Phase 2 Interventional Results available

Directed Topical Drug Delivery for Treatment for PASC Hyposmia

NCT05970731
View directory record Official record
Conditions
Post Acute Sequelae Covid-19 Hyposmia
Interventions
Beclomethasone, Placebo, Microsponge
Drug · Other · Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Nov 3, 2026, 4:23 PM EST
Completed Phase 3 Interventional Results available

ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

NCT01663402
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Alirocumab, Placebo, LMT
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years and older
Enrollment
18,924 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
273
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 218 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Nov 3, 2026, 4:23 PM EST
Completed No phase listed Observational Results available

ProAir Digihaler in COPD Disease Management: A Real World Study

NCT04821869
View directory record Official record
Conditions
COPD, COPD Exacerbation Acute
Interventions
ProAir Digihaler, Digihaler
Drug · Device
Lead sponsor
Pulmonary Research Institute of Southeast Michigan
Other
Eligibility
45 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Farmington Hills, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 13, 2025 · Synced Nov 3, 2026, 4:23 PM EST
Not yet recruiting Phase 4 Interventional

Varenicline for Smoking Cessation in Pancreatitis

NCT07874841
View directory record Official record
Conditions
Pancreatitis, Chronic Pancreatitis, Acute Pancreatitis (AP), Recurrent Acute Pancreatitis
Interventions
Varenicline (VAR)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 3, 2026, 4:23 PM EST
Active, not recruiting No phase listed Observational

Chronic Pain in Rheumatoid Arthritis

NCT05038553
View directory record Official record
Conditions
Arthritis, Rheumatoid, Pain
Interventions
No intervention
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
5
States / cities
Denver, Colorado • Chicago, Illinois • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Nov 3, 2026, 4:23 PM EST
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)

NCT02775903
View directory record Official record
Conditions
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Interventions
Azacitidine, Durvalumab
Drug · Biological
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
12
States / cities
New Haven, Connecticut • Washington D.C., District of Columbia • Gainesville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Nov 3, 2026, 4:23 PM EST
Completed Not applicable Interventional Results available

Electrical Impedance Tomography for Optimization of Positive End-Expiratory Pressure: Acute Respiratory Distress Syndrome

NCT03793842
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, ARDS
Interventions
Usual care, PEEP titration by EIT
Other · Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Nov 3, 2026, 4:23 PM EST